Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: Prospective cohort study before and after implementation of personalized bleeding risks

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Spertus, John A ^a,b   Decker, Carole ^a,b   Gialde, Elizabeth ^a   Jones, Philip G ^a   McNulty, Edward J ^c   Bach, Richard ^d   Chhatriwalla, Adnan K ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c San Francisco Kaiser Hospital   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIRULOG;

AGED; ARTICLE; BLEEDING; CLINICAL COMPETENCE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STRATIFIED SAMPLE; UNITED STATES; VASCULAR ACCESS; VASCULAR CLOSURE DEVICE; ADULT; BLOOD LOSS, SURGICAL; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; HEALTH STATUS INDICATOR; HEMOSTASIS; MIDDLE AGED; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH STATUS INDICATORS; HEMOSTASIS, SURGICAL; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 84926394844     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1302     Document Type: Article

References (39)

1. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA 1993;270:2598-601.
2. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
3. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004;292:2096-104.
4. Brogan GX Jr, Peterson ED, Mulgund J, et al. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes Care 2006;29:9-14.
5. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294:1240-7.
6. Spertus JA, Weiss NS, Every NR, et al, for the Myocardial Infarction Triage and Intervention Project Investigators. The influence of clinical risk factors on the use of angiography and revascularization after acute myocardial infarction. Arch Intern Med 1995;155:2309-16.
7. Yan AT, Yan RT, Tan M, et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med 2007;167:1009-16.
8. Pilote L, Miller DP, Califf RM, et al. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med 1996;335:1198-205.
9. Spertus JA, Furman MI. Translating evidence into practice: are we neglecting the neediest? Arch Intern Med 2007;167:987-8.
10. McAlister FA, Oreopoulos A, Norris CM, et al. Exploring the treatment-risk paradox in coronary disease. Arch Intern Med 2007;167:1019-25.
11. Institute of Medicine. Crossing the quality chasm: a new health system for the twenty-first century. National Academy Press, 2001.
12. Dauerman HL, Rao SV, Resnic FS, et al. Bleeding avoidance strategies: consensus and controversy. J Am Coll Cardiol 2011;58:1-10.
13. Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009;53:2019-27.
14. Rao SV. Implications of bleeding and blood transfusion in percutaneous coronary intervention. Rev Cardiovasc Med 2007;8(suppl 3):S18-26.
15. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-7.
16. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007;100:1364-9.
17. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004;44:1792-800.
18. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-5.
19. Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013;309:1022-9.
20. Jolly SS, Amlani S, Hamon M, et al. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 2009;157:132-40.
21. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-96.
22. Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 2010;303:2156-64.
23. Sanborn TA, Ebrahimi R, Manoukian SV, et al. Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circ Cardiovasc Interv 2010;3:57-62.
24. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16.
25. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
26. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv 2009;2:222-9.
27. Arnold SV, Decker C, Ahmad H, et al. Converting the informed consent from a perfunctory process to an evidence-based foundation for patient decision making. Circ Cardiovasc Qual Outcomes 2008;1:21-8.
28. Soto GE, Jones P, Spertus JA. PRISMTM a web-based framework for deploying predictive clinical models. Computers in Cardiology 2004;31:193-6.
29. Soto GE, Spertus JA. EPOCH and ePRISM: a web-based translational framework for bridging outcomes resaerch and clinical practice. Computers in Cardiology 2007;34:205-8.
30. Spertus JA, Bach R, Bethea C, et al. Improving the process of informed consent for percutaneous coronary intervention: Patient Outcomes from the Patient Risk Information Services Manager (ePRISM) study. Am Heart J 2015;169:234-41.
31. Decker C, Arnold SV, Olabiyi O, et al. Implementing an innovative consent form: the PREDICT experience. Implement Sci 2008;3:58.
32. Patel MR, Jneid H, Derdeyn CP, et al. Arteriotomy closure devices for cardiovascular procedures: a scientific statement from the American Heart Association. Circulation 2010;122:1882-93.
33. R Project for Statistical Computing. R: a language and environment for statistical computing. R Foundation for Statistical Computing, 2006.
34. Rao SC, Chhatriwalla AK, Kennedy KF, et al. Pre-procedural estimate of individualized bleeding risk impacts physicians' utilization of bivalirudin during percutaneous coronary intervention. J Am Coll Cardiol 2013.
35. Mangiacapra F, Patti G, Barbato E, et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012;5:281-9.
36. James BC, Savitz LA. How Intermountain trimmed health care costs through robust quality improvement efforts. Health Aff 2011;30:1185-91.
37. Rao SV, Ohman EM. Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv 2010;3:80-8.
38. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58.
39. Spertus JA, Gialde E, Chhatriwalla AK, et al. Testing an evidencebased, individualized informed consent form to improve patients' experiences with PCI. Circulation 2011;124:2368.